Hyperpermeability of the intestinal mucosa caused by bevacizumab has been reported, indicating excessive IgA secretion and involvement in the onset of IgAN.[2] Gd-IgA1 contributes to the pathogenesis of IgAVN,[6] but its role in causing vasculitis is still under investigation. This evidence concerns the gene IGHA1 and vasculitis.